Literature DB >> 6773987

Purification and biochemical characterization of nuclear ribonucleoprotein antigen using purified antibody from serum of a patient with mixed connective tissue disease.

M Takano, P F Agris, G C Sharp.   

Abstract

We have achieved a high degree of purification of nuclear ribonucleoprotein antigen from calf thymus nuclear extract through antibody affinity chromatography. Antibody to nuclear ribonucleoprotein was purified from the serum of a patient with mixed connective tissue disease and Sepharose 4B was covalently coupled with the purified human antibody. The sodium thiocyanate eluate from the affinity column contained active ribonucleoprotein antigen and the specific activity of the antigen in this eluate was 488 times higher than the original nuclear extract. The protein component of the eluate consisted of six polypeptides determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Two of them were shown to be antigenic by a hemagglutination inhibition test. The molecular weights of these two peptides were approximately 13,000 and those of the other four were 13,000, 13,000, 30,000, and 65,000. The ribonucleic acid component of the eluate was shown by urea-polyacrylamide gel electrophoresis to contain five polynucleotides. Two of the five, estimated to contain 40 and 60 nucleosides, had antigenic activity. The other three polynucleotides which had more than 77 nucleosides had no antigenic activity. No modified nucleosides were found in these ribonucleic acid molecules. Even in this highly purified ribonucleoprotein antigen, Sm antigen was detected by immunodiffusion. This evidence indicated that there are some molecular associations between ribonucleoprotein and Sm antigens as has previously been suggested.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773987      PMCID: PMC371483          DOI: 10.1172/JCI109809

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Profiles of antinuclear antibodies in systemic rheumatic diseases.

Authors:  D D Notman; N Kurata; E M Tan
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

2.  Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease.

Authors:  M D Parker
Journal:  J Lab Clin Med       Date:  1973-11

3.  Physical association of two nuclear antigens and mutual occurrence of their antibodies: the relationship of the SM and RNAprotein (MO) systems in SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors.

Authors:  D Alarcon-Segovia; A Ruiz-Arguelles; E Fishbein
Journal:  Nature       Date:  1978-01-05       Impact factor: 49.962

7.  Isolation and characterization of nuclear ribonucleoprotein complexes using human anti-nuclear ribonucleoprotein antibodies.

Authors:  A S Douvas; W E Stumph; P Reyes; E M Tan
Journal:  J Biol Chem       Date:  1979-05-10       Impact factor: 5.157

8.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

9.  Characterization of a unique enzyme complex composed of S-adenosyl-L-methionine-tRNA-methyltransferase and aminoacyl-tRNA synthetase activities.

Authors:  P F Agris; D Setzer; C W Gehrke
Journal:  Nucleic Acids Res       Date:  1977-11       Impact factor: 16.971

10.  Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy.

Authors:  G C Sharp; W S Irvin; R L LaRoque; C Velez; V Daly; A D Kaiser; H R Holman
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

View more
  13 in total

1.  Heterogeneity of RNP and Sm autoantigens in relation to the cell sources and the activated state of the cells.

Authors:  F Hiepe; K Yamamoto; A Takeuchi; E Apostoloff; T Miyamoto
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes.

Authors:  J Craft; T Mimori; T L Olsen; J A Hardin
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

3.  Scl-86, a marker antigen for diffuse scleroderma.

Authors:  W J van Venrooij; S O Stapel; H Houben; W J Habets; C G Kallenberg; E Penner; L B van de Putte
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 4.  Purification of antigens and monoclonal antibodies.

Authors:  D Williams
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

Review 5.  Current perspectives on serological reactions in SLE patients.

Authors:  M Reichlin
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

6.  Antibodies to heterogeneous nuclear ribonucleoproteins in sera from patients with rheumatic autoimmune diseases.

Authors:  M Zouali; A Eyquem
Journal:  J Clin Immunol       Date:  1984-05       Impact factor: 8.317

7.  Human U1 and U2 small nuclear ribonucleoproteins contain common and unique polypeptides.

Authors:  C S Kinlaw; S K Dusing-Swartz; S M Berget
Journal:  Mol Cell Biol       Date:  1982-10       Impact factor: 4.272

8.  Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease.

Authors:  W J Habets; D J de Rooij; M H Salden; A P Verhagen; C A van Eekelen; L B van de Putte; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

9.  Analysis of speckled fluorescent antinuclear antibody test antisera using electrofocused nuclear antigens.

Authors:  T B Okarma; J A Krueger; H R Holman
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Separation of two molecular species of the Sm antigen by affinity chromatography with murine monoclonal and human anti-nuclear autoantibodies.

Authors:  R R Buchanan; P J Venables; A Morgan; N A Staines; P R Smith; R N Maini
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.